← Leaderboards
Wafik S El-Deiry
University Of Pennsylvania
$15,004,115
Attributed
$15,116,595
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$21,511,325 · 15
By mechanism
R01$13,204,212 · 7
U54$6,394,730 · 3
P01$788,047 · 1
R21$769,364 · 2
R43$224,960 · 1
P30$130,012 · 1
Top collaborators
- Gary L Olson1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Xiaowei Xu$9,845,570
- Meenhard Herlyn$50,214,821
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorNeoplastic CellMalignant NeoplasmsIn VivoSignal TransductionCellsPathway InteractionsCancer TherapySmall MoleculeBaseLeadClinicClinical TrialsTranslatingFamilyCancer CellImageTumor XenograftInsightMutationCell DeathResistanceColon CarcinomaMolecular
Grant awards (68)
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway$474,416
R01 · FY2023 · CA · contact PI
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway$93,169
R01 · FY2023 · CA · contact PI
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway$474,416
R01 · FY2022 · CA · contact PI
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway$86,816
R01 · FY2022 · CA · contact PI
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway$484,099
R01 · FY2021 · CA · contact PI
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway$485,090
R01 · FY2020 · CA · contact PI
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway$487,736
R01 · FY2019 · CA · contact PI
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy$374,553
R01 · FY2018 · CA · contact PI
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy$73,225
R01 · FY2018 · CA · contact PI
Molecular Therapeutics Program (04)$38,271
P30 · FY2018 · CA · contact PI
Molecular Therapeutics Program (04)$10,869
P30 · FY2018 · CA · contact PI
Molecular Therapeutics Program (04)$5,966
P30 · FY2018 · CA · contact PI
TIC10 anti-tumor effect through regulation of Foxo3a and TRAIL$378,052
R01 · FY2017 · CA · contact PI
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy$374,705
R01 · FY2017 · CA · contact PI
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy$73,225
R01 · FY2017 · CA · contact PI
Molecular Therapeutics Program (04)$38,269
P30 · FY2017 · CA · contact PI
TIC10 anti-tumor effect through regulation of Foxo3a and TRAIL$368,851
R01 · FY2016 · CA · contact PI
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy$365,779
R01 · FY2016 · CA · contact PI
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy$49,090
R01 · FY2016 · CA · contact PI
Molecular Therapeutics Program (04)$36,637
P30 · FY2016 · CA · contact PI
TIC10 anti-tumor effect through regulation of Foxo3a and TRAIL$368,896
R01 · FY2015 · CA · contact PI
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy$357,174
R01 · FY2015 · CA · contact PI
Immunopheonotyping of circulating tumor cells$194,119
R21 · FY2015 · CA · contact PI
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy$316,656
R01 · FY2014 · CA · contact PI
TIC10 anti-tumor effect through regulation of Foxo3a and TRAIL$301,664
R01 · FY2014 · CA · contact PI
TRAIL Upregulation by TIC10 Analogs$224,960
R43 · FY2014 · CA
Immunopheonotyping of circulating tumor cells$209,192
R21 · FY2014 · CA · contact PI
TIC10 anti-tumor effect through regulation of Foxo3a and TRAIL$5,518
R01 · FY2014 · CA · contact PI
TIC10 anti-tumor effect through regulation of Foxo3a and TRAIL$316,682
R01 · FY2013 · CA · contact PI
Modulation of sensitivity & imaging therapeutic response of hypoxic cancer cells$293,448
R01 · FY2013 · CA · contact PI
Modulation of sensitivity & imaging therapeutic response of hypoxic cancer cells$28,752
R01 · FY2013 · CA · contact PI
Modulation of sensitivity & imaging therapeutic response of hypoxic cancer cells$312,178
R01 · FY2012 · CA · contact PI
Novel myeloma stem cell markers for therapy$166,388
R21 · FY2012 · CA · contact PI
Modulation of sensitivity & imaging therapeutic response of hypoxic cancer cells$82,591
R01 · FY2012 · CA · contact PI
Modulation of sensitivity & imaging therapeutic response of hypoxic cancer cells$312,178
R01 · FY2011 · CA · contact PI
Novel myeloma stem cell markers for therapy$199,665
R21 · FY2011 · CA · contact PI
Modulation of sensitivity & imaging therapeutic response of hypoxic cancer cells$52,003
R01 · FY2011 · CA · contact PI
Modulation of sensitivity & imaging therapeutic response of hypoxic cancer cells$321,833
R01 · FY2010 · CA · contact PI
Hypoxia signaling to checkpoint activation and apoptosis$266,285
R01 · FY2010 · CA · contact PI
Modulation of sensitivity & imaging therapeutic response of hypoxic cancer cells$321,813
R01 · FY2009 · CA · contact PI
Hypoxia signaling to checkpoint activation and apoptosis$267,266
R01 · FY2009 · CA · contact PI
Hypoxia signaling to checkpoint activation and apoptosis$346,013
R01 · FY2008 · CA · contact PI
Network for Translational Research: Optical Imaging$1,224,158
U54 · FY2007 · CA · contact PI
Hypoxia signaling to checkpoint activation and apoptosis$267,266
R01 · FY2007 · CA · contact PI
Network for Translational Research: Optical Imaging$1,353,739
U54 · FY2006 · CA · contact PI
Unique BRCA1 transcriptional response leading to repair$379,751
R01 · FY2006 · CA · contact PI
CARP, A Novel Cell Death Regulator$331,351
R01 · FY2006 · CA · contact PI
Hypoxia signaling to checkpoint activation and apoptosis$274,469
R01 · FY2006 · CA · contact PI
Network for Translational Research: Optical Imaging$1,473,111
U54 · FY2005 · CA
Unique BRCA1 transcriptional response leading to repair$388,891
R01 · FY2005 · CA
CARP, A Novel Cell Death Regulator$339,325
R01 · FY2005 · CA
Network for Translational Research: Optical Imaging$1,303,111
U54 · FY2004 · CA
Unique BRCA1 transcriptional response leading to repair$359,101
R01 · FY2004 · CA
CARP, A Novel Cell Death Regulator$329,793
R01 · FY2004 · CA
Network for Translational Research: Optical Imaging$1,040,611
U54 · FY2003 · CA
Unique BRCA1 transcriptional response leading to repair$317,396
R01 · FY2003 · CA
CARP, A Novel Cell Death Regulator$282,130
R01 · FY2003 · CA
Imaging Cancer Therapeutic Response$0
U54 · FY2003 · CA
Core--Bioluminescence$0
U54 · FY2003 · CA
Unique BRCA1 transcriptional response leading to repair$317,396
R01 · FY2002 · CA
CARP, A Novel Cell Death Regulator$282,130
R01 · FY2002 · CA
KILLER/DR5 APOPTOSIS IN DNA DAMAGE SENSITIVE CELLS$140,673
P01 · FY2002 · CA
KILLER/DR5 AND TUMORIGENESIS$213,151
R01 · FY2001 · CA
KILLER/DR5 APOPTOSIS IN DNA DAMAGE SENSITIVE CELLS$140,673
P01 · FY2001 · CA
KILLER/DR5 AND TUMORIGENESIS$207,890
R01 · FY2000 · CA
KILLER/DR5 APOPTOSIS IN DNA DAMAGE SENSITIVE CELLS$183,014
P01 · FY2000 · CA
KILLER/DR5 APOPTOSIS IN DNA DAMAGE SENSITIVE CELLS$183,014
P01 · FY2000 · CA
KILLER/DR5 APOPTOSIS IN DNA DAMAGE SENSITIVE CELLS$140,673
P01 · FY2000 · CA